Armata Pharmaceuticals (ARMP) Cash from Investing Activities (2013 - 2026)
Armata Pharmaceuticals (ARMP) reported Cash from Investing Activities of -$63000.0 for Q1 2026, up 36.36% on a YoY basis from -$46200.0 in Q1 2025, and down 21.15% sequentially from -$52000.0 in Q4 2025.
Armata Pharmaceuticals (ARMP) Cash from Investing Activities (2013 - 2026) Analysis & Trends
Armata Pharmaceuticals (ARMP) has 14 years of Cash from Investing Activities data on file, last reported at -$63000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities rose 36.36% year-over-year to -$63000.0; the trailing twelve-month figure through Mar 2026 stood at -$506000.0 (up 70.72% YoY), and the FY2025 full-year result was -$542000.0, up 71.15% from the prior year.
- Cash from Investing Activities slipped to -$63000.0 in Q1 2026, from -$52000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $455000.0 in Q4 2022 to a low of -$3.5 million in Q3 2023.
- A 5-year average of -$754647.1 and a median of -$242000.0 in 2025 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities soared 299.56% in 2022 and plunged 751.69% in 2023, its largest moves.
- Tracing ARMP's Cash from Investing Activities over 5 years: stood at $455000.0 in 2022, then tumbled by 625.27% to -$2.4 million in 2023, then jumped by 103.22% to $77000.0 in 2024, then plunged by 167.53% to -$52000.0 in 2025, then dropped by 21.15% to -$63000.0 in 2026.
- Business Quant data shows ARMP's Cash from Investing Activities at -$63000.0 in Q1 2026, -$52000.0 in Q4 2025, and -$242000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | - |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.90 Bn | 61.14 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.46 Bn | 37.46 Bn | - | 172.62 Mn |
| 10 | Armata Pharmaceuticals | 174.25 Mn | 169.45 Mn | - | -63,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -63,000.00 |
| Mar 31, 2026 | -63,000.00 |
| Dec 31, 2025 | -52,000.00 |
| Dec 31, 2025 | -52,000.00 |
| Sep 30, 2025 | -242,000.00 |
| Sep 30, 2025 | -242,000.00 |
| Jun 30, 2025 | -149,000.00 |
| Jun 30, 2025 | -149,000.00 |
| Mar 31, 2025 | -99,000.00 |
| Mar 31, 2025 | -99,000.00 |
| Dec 31, 2024 | 77,000.00 |
| Dec 31, 2024 | 77,000.00 |
| Sep 30, 2024 | -340,000.00 |
| Sep 30, 2024 | -340,000.00 |
| Jun 30, 2024 | -1.37 Mn |
| Jun 30, 2024 | -1.37 Mn |
| Mar 31, 2024 | -250,000.00 |
| Mar 31, 2024 | -250,000.00 |
| Dec 31, 2023 | -2.39 Mn |
| Dec 31, 2023 | -2.39 Mn |